MW Sarepta Therapeutics stock falls after DMM patient dies of liver failure

Sarepta Therapeutics Inc.'s stock was down 21.6% in premarket trades on Tuesday after the commercial-stage biopharmaceutical company said a patient died from liver failure after using its drug Elevidys, which is used to treat Duchenne muscular dystrophy.

While liver failure is a known possible side effect of Elevidys, it had not yet been reported until now, Sarepta (SRPT) said.

"Acute liver failure leading to death represents a severity of acute liver injury notpreviously reported for Elevidys, which to date has been used to treat more than 800 patients inclinical trials or as a prescribed therapy," the company said.

Prior to Tuesday's moves, Sarepta's stock was down 16.7% so far in 2025, while Nasdaq COMP has dropped 7.8%.

-Steve Gelsi

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

March 18, 2025 09:02 ET (13:02 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.